Skip to content

Illness Expectations in Pulmonary Fibrosis

Between Beliefs and Expectations in Pulmonary Fibrosis: a Prospective Cohort Study With Mixed Methods.

Status
Enrolling by invitation
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT06327360
Acronym
CAMFP
Enrollment
130
Registered
2024-03-25
Start date
2023-10-10
Completion date
2025-10-01
Last updated
2024-04-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Fibrosis

Keywords

Pulmonary Fibrosis, Clinical Psychology, Rehabilitation Psychology, Illness Expectations, Illness Perceptions, Adherence to treatment

Brief summary

This study aims to delve into the constructs of illness beliefs and expectations among patients with Pulmonary Fibrosis, exploring how these beliefs and expectations may influence the treatment journey, including oxygen therapy, non-invasive ventilation therapy, and pharmacological treatments.

Interventions

The questionnaires will be completed at the time of enrollment (T0), and at the 6- and 12-month follow-ups.

Sponsors

Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico
CollaboratorOTHER
FIMARP ONLUS - FEDERAZIONE ITALIANA IPF E MALATTIE POLMONARI RARE
CollaboratorUNKNOWN
Fondazione Don Carlo Gnocchi Onlus
Lead SponsorOTHER

Study design

Observational model
COHORT
Time perspective
PROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Patients with pulmonary fibrosis * Patients using oxygen therapy * Patients using non-invasive ventilation * Patients undergoing pharmacological treatment * Patients who speak and understand the Italian language

Exclusion criteria

* Patients who do not provide their consent * Patients without pulmonary fibrosis * Patients with psychiatric disorders or cognitive impaiment * Patients who don't speak or understand Italian language

Design outcomes

Primary

MeasureTime frameDescription
Illness Cognitionsfrom October 2023 to October 2025Illness Cognition Questionnaire (ICQ), a questionnaire assessing three ways of cognitively evaluating the stressful and adverse nature of a chronic illness: helplessness, acceptance, and perceived benefits.
Pharmacological treatment Beliefsfrom October 2023 to October 2025Assessed using the Beliefs about Medicines Questionnaire (BMQ), a tool designed to evaluate individuals' beliefs about medications. It has been validated for use in patients with chronic illnesses and has been shown to predict treatment adherence in other groups, such as individuals with asthma.
Illness Expectationsfrom October 2023 to October 2025Specific questions formulated to assess explicit illness expectations in Pulmonary Fibrosis are proposed.
Adherence to Pharmacological Treatmentfrom October 2023 to October 2025Types of medications taken (Pirfenidone/Nintedanib/Other); assessed as the ratio between the received daily dose (RDD) and the prescribed daily dose (PDD); also evaluated using the Medication Adherence Report Scale (MARS-5), a 5-item questionnaire.
Adherence to Oxygen Therapyfrom October 2023 to October 2025Use of oxygen and respective quantities (liters/minute at rest and during exertion).
Adherence to Non invasive ventilationfrom October 2023 to October 2025Use of Non-Invasive Ventilation (nighttime/daytime or both; prescribed and actual hours of usage).
Illness beliefsfrom October 2023 to October 2025Assessed using the Brief Illness Perception Questionnaire (B-IPQ), a nine-question scale designed to rapidly assess cognitive and emotional representations of the illness. Assessed using the Brief Illness Perception Questionnaire (B-IPQ), a nine-question scale designed to rapidly assess cognitive and emotional representations of the illness.

Secondary

MeasureTime frameDescription
Clinical and medical datafrom October 2023 to October 2025Weight and height (for calculation of Body Mass Index, BMI); comorbidities (diabetes, hypertension, hypercholesterolemia, presence of other conditions), perceived symptoms (e.g., dyspnea, cough, chest pain, fatigue and weakness, muscle and joint pains, weight loss...). Additionally, parameters from respiratory function tests (particularly Forced Vital Capacity (FVC) and Diffusing Capacity of the Lungs for Carbon Monoxide (DLCO), arterial blood gas analysis) will be recorded. These data will be extracted from the latest available medical report and therefore from the last pulmonary visit conducted as part of routine clinical practice (please note that medical visits paid for by this project are not included).
Socio-demographic variablesfrom October 2023 to October 2025Gender, age, smoking status, and number of cigarettes smoked per day. Additionally, factors such as family history of respiratory diseases, alcohol use (frequency), physical activity (frequency and type), level of education, marital status, onset of initial symptoms, and date of diagnosis will be considered.

Countries

Italy

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026